TP53 and acute myeloid leukemia: Finally, a pilot trial of atorvastatin in tumour protein 53 (p53)-mutated and p53 wild-type malignancies including solid tumours and AML is actively recruiting (NCT03560882; data accessed: 14 March 2020).